SLC39A6 and breast cancer: Therefore, this study aimed to determine the prognostic value of SLC39A6 by assessing the associations between SLC39A6 protein expression, mRNA expression and gene copy number with clinicopathological parameters, expression of other key ER-related proteins and patient outcomes utilising large, well-characterised BC cohorts, with an emphasis on the luminal ER + subtype.